First-ever covalent irreversible inhibition of a protease central to hepatitis C infection
Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease ...
